FDA Reports Significant Progress in Reducing Animal Testing for Drug Development

The U.S. Food and Drug Administration (FDA) has announced it has met its initial objectives in its roadmap to decrease the use of animal testing in preclinical safety studies for drug development. This achievement, one year after the roadmap’s publication, signifies a major step toward modernizing drug evaluation processes by embracing innovative, human-centric scientific methods. The agency’s efforts are aimed at not only enhancing the accuracy of drug safety predictions but also potentially lowering research and development costs, which could ultimately lead to more affordable medications for consumers.

The FDA’s initiative stems from the understanding that animal models are not always reliable predictors of how drugs will perform in humans. Historically, a large percentage of drugs that show promise in animal studies have failed to gain FDA approval, often due to safety or efficacy issues that only become apparent in human trials. To bridge this gap, the agency is actively promoting the adoption of new approach methodologies (NAMs). These advanced techniques include sophisticated in vitro systems, computational modeling, and platforms derived from human cells, all of which offer a more accurate representation of human biology and a better forecast of drug responses.

In contrast to previous industry guidance, the FDA’s 2025 roadmap established concrete timelines for phasing out animal testing in instances where equally effective or superior alternatives are available. The agency has now released a comprehensive report detailing its progress in implementing this roadmap and outlining its future plans. Key actions taken over the past year include the release of draft guidance concerning the reduction or elimination of nonhuman primate testing in the development of monoclonal antibodies. Additionally, the FDA updated its guidance to facilitate a shift away from horseshoe crab-derived endotoxin testing, a change that could potentially spare over a million animals annually. The agency is also working to reduce or eliminate the requirement for animal testing when drugs have already demonstrated safety through widespread human use in other countries.

Further progress has been made with the release of draft guidance that broadens the acceptance of weight-of-evidence approaches. This encourages drug developers to more readily integrate in vitro assays, computational toxicology, and other human-relevant models to gather evidence across a range of safety endpoints. Demonstrating the efficacy of cutting-edge computational models, the FDA has qualified its first artificial intelligence-based drug development tool, showcasing its utility in supporting regulatory decision-making. To further assist researchers, the agency has launched a searchable database that clarifies where alternative methods are deemed acceptable and has fostered close collaborations with international regulatory bodies to harmonize strategies.

To ensure the continuation of this momentum, the FDA has implemented critical infrastructure, including a permanent framework for qualifying innovative drug development tools, cross-center scientific review processes, and a formal partnership with the National Institutes of Health. These combined efforts are driving a fundamental shift towards prioritizing human-relevant science as the standard for drug evaluation. This transition is anticipated to improve the prediction of drug safety, expedite development timelines, decrease costs, and expand patient access to novel therapies, while significantly decreasing the reliance on animal testing. The FDA intends to continue its collaborative work with partners across government, industry, and academia to further expand the use of these advanced approaches and continue the modernization of drug development.

Article by Mel Anara, based upon information from the U.S. Food and Drug Administration

---